Adagio Medical Holdings, Inc.(ADGM)Earnings, Financials & Key Ratios
ADGM•NASDAQ
$0.95
$15M mkt cap·Price updated May 7, 2026
AboutAdagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.Show more
- Revenue$269K-10.3%
- EBITDA-$70M-155.7%
- Net Income-$54M-40.9%
- EPS (Diluted)-3.54+27.2%
- Gross Margin-620.07%-84.9%
- EBITDA Margin-26056.51%-185.2%
- Operating Margin-23226.77%-149.4%
- Net Margin-19986.25%-57.2%
- ROE-270%
- Debt/Equity0.82
ADGM Key Insights
Adagio Medical Holdings, Inc. (ADGM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 93.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ADGM Price & Volume
Adagio Medical Holdings, Inc. (ADGM) stock price & volume — 10-year historical chart
Loading chart...
ADGM Growth Metrics
Adagio Medical Holdings, Inc. (ADGM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-0.12%
TTM-126.34%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-170.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-598.12%
Return on Capital
10 Years-12616.86%
5 Years-12616.86%
3 Years-18870.54%
Last Year-37413.17%
ADGM Peer Comparison
Adagio Medical Holdings, Inc. (ADGM) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAT | 34.93M | 0.87 | -1.40 | -5.71% | ||||
 CRMD | 621.26M | 7.92 | 3.88 | 6.17% | 52.31% | 58.5% | 0.37 | |
 ATRC | 1.41B | 27.80 | -115.83 | 14.88% | -0.83% | -0.95% | 0.18 | |
 ABLV | 33.15M | 0.67 | -3.72 | -13.47% | 2.07% | 27.9% | 1.57 | |
 MEDP | 12.24B | 428.71 | 28.06 | 19.97% | 17.19% | 120.89% | 0.55 | |
 BSX | 84.08B | 56.58 | 29.16 | 19.87% | 14.4% | 12.4% | 0.51 | |
 ABT | 151.3B | 87.01 | 11.39 | 4.59% | 31.88% | 27.26% | 0.32 | |
 IRTC | 4.1B | 124.87 | -89.83 | 26.24% | -3.53% | -20.6% | 4.79 |
Compare ADGM vs Peers
Adagio Medical Holdings, Inc. (ADGM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADGM Income Statement
Adagio Medical Holdings, Inc. (ADGM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Sales/Revenue | 270K | 189K | 300K | 269K | -143K |
| Revenue Growth % | - | -30% | 58.73% | -10.33% | -126.34% |
| Cost of Goods Sold | 1.16M | 875K | 1.31M | 1.94M | 925K |
| COGS % of Revenue | 428.89% | 462.96% | 435.33% | 720.07% | - |
| Gross Profit | -888K▲ 0% | -686K▲ 22.7% | -1.01M▼ 46.6% | -1.67M▼ 65.8% | -1.07M▲ 0% |
| Gross Margin % | -328.89% | -362.96% | -335.33% | -620.07% | - |
| Gross Profit Growth % | - | 22.75% | -46.65% | -65.81% | - |
| Operating Expenses | 19.76M | 23.23M | 26.94M | 60.81M | 67.58M |
| OpEx % of Revenue | 7317.41% | 12289.42% | 8978.67% | 22606.69% | - |
| Selling, General & Admin | 4.4M | 5.37M | 11.54M | 6.98M | 5.71M |
| SG&A % of Revenue | 1630.37% | 2842.33% | 3845.67% | 2593.31% | - |
| Research & Development | 15.36M | 17.86M | 15.4M | 4.63M | 11.82M |
| R&D % of Revenue | 5687.04% | 9447.09% | 5133% | 1722.68% | - |
| Other Operating Expenses | 0 | 0 | 0 | 49.2M | 3M |
| Operating Income | -20.64M▲ 0% | -23.91M▼ 15.8% | -27.94M▼ 16.8% | -62.48M▼ 123.6% | -68.62M▲ 0% |
| Operating Margin % | -7646.3% | -12652.38% | -9314% | -23226.77% | - |
| Operating Income Growth % | - | -15.83% | -16.85% | -123.61% | - |
| EBITDA | -20.31M | -23.42M | -27.41M | -70.09M | -67.46M |
| EBITDA Margin % | -7521.85% | -12390.48% | -9136.67% | -26056.51% | - |
| EBITDA Growth % | - | -15.31% | -17.05% | -155.72% | -121.46% |
| D&A (Non-Cash Add-back) | 336K | 495K | 532K | -7.61M | 1.16M |
| EBIT | -19.94M | -23.54M | -27.94M | -54.87M | -78.18M |
| Net Interest Income | 3K | -98K | -1.66M | 1.52M | -1.03M |
| Interest Income | 3K | 39K | 3K | 423K | 1.1M |
| Interest Expense | 0 | 137K | 1.66M | -1.1M | 2.13M |
| Other Income/Expense | 707K | 240K | -10.2M | 8.72M | -1.4M |
| Pretax Income | -19.94M▲ 0% | -23.67M▼ 18.7% | -38.15M▼ 61.1% | -53.76M▼ 40.9% | -70.02M▲ 0% |
| Pretax Margin % | -7384.44% | -12525.4% | -12715.33% | -19986.25% | 48966.89% |
| Income Tax | 0 | 0 | 0 | 0 | 9.12M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -13.03% |
| Net Income | -19.94M▲ 0% | -23.67M▼ 18.7% | -38.15M▼ 61.1% | -53.76M▼ 40.9% | -74.58M▲ 0% |
| Net Margin % | -7384.44% | -12525.4% | -12715.33% | -19986.25% | - |
| Net Income Growth % | - | -18.73% | -61.14% | -40.94% | -170.98% |
| Net Income (Continuing) | -19.94M | -23.67M | -38.15M | -53.76M | -79.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.34▲ 0% | 0.06▲ 116.4% | -4.86▼ 8841.0% | -3.54▲ 27.2% | -4.85▲ 0% |
| EPS Growth % | - | 116.35% | -8841.01% | 27.16% | -598.12% |
| EPS (Basic) | -0.34 | 0.06 | -4.86 | -3.54 | - |
| Diluted Shares Outstanding | 19.19M | 19.19M | 7.86M | 15.2M | 15.38M |
| Basic Shares Outstanding | 19.19M | 19.19M | 7.86M | 15.2M | 15.38M |
| Dividend Payout Ratio | - | - | - | - | - |
ADGM Balance Sheet
Adagio Medical Holdings, Inc. (ADGM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Total Current Assets | 19.72M | 6.73M | 5.18M | 25.35M | 8.14M |
| Cash & Short-Term Investments | 18.85M | 5.55M | 1.38M | 20.59M | 4.67M |
| Cash Only | 18.85M | 5.55M | 1.38M | 20.59M | 4.67M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 33K | 0 | 71K | 35K | 0 |
| Days Sales Outstanding | 44.61 | - | 86.38 | 47.49 | -22.97 |
| Inventory | 334K | 367K | 3.32M | 2.57M | 1.55M |
| Days Inventory Outstanding | 105.28 | 153.09 | 928.43 | 483.53 | 815.33 |
| Other Current Assets | 241K | 527K | 177K | 222K | 1.92M |
| Total Non-Current Assets | 1.72M | 1.97M | 1.64M | 23.1M | 23.4M |
| Property, Plant & Equipment | 1.7M | 1.94M | 1.62M | 2.15M | 2.46M |
| Fixed Asset Turnover | 0.16x | 0.10x | 0.19x | 0.13x | -0.06x |
| Goodwill | 0 | 0 | 0 | 13.97M | 13.97M |
| Intangible Assets | 0 | 0 | 0 | 6.97M | 6.97M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 22K | 26K | 23K | 14K | 40K |
| Total Assets | 21.44M▲ 0% | 8.7M▼ 59.4% | 6.83M▼ 21.5% | 48.45M▲ 609.9% | 31.55M▲ 0% |
| Asset Turnover | 0.01x | 0.02x | 0.04x | 0.01x | -0.00x |
| Asset Growth % | - | -59.44% | -21.52% | 609.86% | 1227.3% |
| Total Current Liabilities | 2.59M | 12.97M | 47.18M | 7.76M | 9.7M |
| Accounts Payable | 578K | 1.01M | 3.83M | 2.84M | 1.02M |
| Days Payables Outstanding | 182.18 | 421.73 | 1.07K | 535.16 | 772.02 |
| Short-Term Debt | 0 | 9.5M | 38.13M | 143K | 180K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 843K | 0 | 1.64M | 2.16M | 8.5M |
| Current Ratio | 7.62x | 0.52x | 0.11x | 3.27x | 3.27x |
| Quick Ratio | 7.49x | 0.49x | 0.04x | 2.93x | 2.93x |
| Cash Conversion Cycle | -32.3 | - | -55.59 | -4.14 | 20.33 |
| Total Non-Current Liabilities | 91.47M | 91.61M | 91.67M | 20.77M | 23.16M |
| Long-Term Debt | 0 | 0 | 143K | 16.08M | 21.79M |
| Capital Lease Obligations | 0 | 134K | 52K | 46K | 1.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 883K | 3.53M |
| Other Non-Current Liabilities | 91.47M | 91.47M | 91.48M | 3.77M | 11.85M |
| Total Liabilities | 94.06M | 104.57M | 138.85M | 28.54M | 32.86M |
| Total Debt | 0 | 9.8M | 38.4M | 16.27M | 21.97M |
| Net Debt | -18.85M | 4.25M | 37.02M | -4.32M | 17.29M |
| Debt / Equity | - | - | - | 0.82x | 0.82x |
| Debt / EBITDA | - | - | - | - | -0.33x |
| Net Debt / EBITDA | - | - | - | - | -0.26x |
| Interest Coverage | - | -174.55x | -16.84x | - | -36.69x |
| Total Equity | -72.62M▲ 0% | -95.88M▼ 32.0% | -132.02M▼ 37.7% | 19.91M▲ 115.1% | -1.31M▲ 0% |
| Equity Growth % | - | -32.03% | -37.7% | 115.08% | 253.44% |
| Book Value per Share | -3.78 | -5.00 | -16.81 | 1.31 | -0.09 |
| Total Shareholders' Equity | -72.62M | -95.88M | -132.02M | 19.91M | -1.31M |
| Common Stock | 1K | 1K | 1K | 2K | 2K |
| Retained Earnings | -73.39M | -97.06M | -133.65M | -70.59M | -92.3M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | 28K | 17K | 1K | -95K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
ADGM Cash Flow Statement
Adagio Medical Holdings, Inc. (ADGM) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|
| Cash from Operations | -19.31M | -22.41M | -25.65M | -29.46M | -29.46M |
| Operating CF Margin % | -7150.74% | -11858.2% | -8550.67% | -10951.3% | - |
| Operating CF Growth % | - | -16.08% | -14.46% | -14.84% | 90.94% |
| Net Income | -19.94M | -23.67M | -36.59M | -75.04M | -74.58M |
| Depreciation & Amortization | 336K | 495K | 548K | 1.39M | 966K |
| Stock-Based Compensation | 339K | 365K | 442K | 0 | 452K |
| Deferred Taxes | 0 | 0 | 0 | -1.92M | -1.92M |
| Other Non-Cash Items | -623K | 71K | 9.98M | 40.33M | 53.03M |
| Working Capital Changes | 579K | 330K | -32K | 5.79M | 4.63M |
| Change in Receivables | 40K | 33K | -70K | 35K | 89K |
| Change in Inventory | -473K | 35K | -2.98M | 626K | 2.58M |
| Change in Payables | 279K | 436K | 0 | -4.56M | -3.39M |
| Cash from Investing | -1.27M | -500K | -340K | -1.65M | -1.57M |
| Capital Expenditures | -1.26M | -502K | -333K | -1.65M | -1.57M |
| CapEx % of Revenue | 465.93% | 265.61% | 111% | 612.64% | - |
| Acquisitions | 0 | 2K | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | -14K | 0 | -7K | 0 | 0 |
| Cash from Financing | 130K | 9.53M | 21.88M | 15.63M | 0 |
| Debt Issued (Net) | 0 | 9.5M | 21.86M | 15.63M | 0 |
| Equity Issued (Net) | 0 | 25K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 130K | 0 | 18K | 0 | 0 |
| Net Change in Cash | -20.38M▲ 0% | 5.05M▲ 124.8% | -4.16M▼ 182.5% | 20.57M▲ 593.9% | -23.59M▲ 0% |
| Free Cash Flow | -20.58M▲ 0% | -22.9M▼ 11.3% | -25.98M▼ 13.5% | -31.11M▼ 19.7% | -23.55M▲ 0% |
| FCF Margin % | -7621.85% | -12118.52% | -8661.67% | -11563.94% | - |
| FCF Growth % | - | -11.3% | -13.45% | -19.71% | 22.53% |
| FCF per Share | -1.07 | -1.19 | -3.31 | -2.05 | -2.05 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.95x | 0.67x | 0.55x | 0.32x |
| Interest Paid | 0 | 0 | 208K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
ADGM Key Ratios
Adagio Medical Holdings, Inc. (ADGM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -270% | -752.11% |
| Return on Invested Capital (ROIC) | - | - | - | -303.46% |
| Gross Margin | -362.96% | -335.33% | -620.07% | 746.85% |
| Net Margin | -12525.4% | -12715.33% | -19986.25% | 52154.8% |
| Debt / Equity | - | - | 0.82x | 0.82x |
| Interest Coverage | -174.55x | -16.84x | - | -36.69x |
| FCF Conversion | 0.95x | 0.67x | 0.55x | 0.32x |
| Revenue Growth | -30% | 58.73% | -10.33% | -126.34% |
ADGM Frequently Asked Questions
Adagio Medical Holdings, Inc. (ADGM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adagio Medical Holdings, Inc. (ADGM) reported $-0.1M in revenue for fiscal year 2024. This represents a 153% decrease from $0.3M in 2021.
Adagio Medical Holdings, Inc. (ADGM) saw revenue decline by 10.3% over the past year.
Adagio Medical Holdings, Inc. (ADGM) reported a net loss of $74.6M for fiscal year 2024.
Dividend & Returns
Adagio Medical Holdings, Inc. (ADGM) has a return on equity (ROE) of -270.0%. Negative ROE indicates the company is unprofitable.
Adagio Medical Holdings, Inc. (ADGM) had negative free cash flow of $23.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More ADGM
Adagio Medical Holdings, Inc. (ADGM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates